Stock has run ahead of the business
Over 4 years the stock returned 44.4% a year while profit shrank 3.5% a year.
Importance 64 / 95 · business vs stock
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Over 4 years the stock returned 44.4% a year while profit shrank 3.5% a year.
Importance 64 / 95 · business vs stock
Trades at 88.25× earnings — 95% above the pharmaceuticals median of 45.29×.
Importance 52 / 95 · valuation
Free cash flow has been positive in 5 of the last 5 years.
Importance 44 / 95 · cash quality
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 4.0% a year over 4 years, from ₹8,880 cr in FY2022 to ₹10,388 cr in FY2026. Net profit fell 3.0% a year over the same period.
Net profit grew 17.2% year on year (FY2025 → FY2026).
Rule PROFIT_GREW_YOY
Revenue has compounded at 4.2% a year over 4 years (₹8,960 → ₹10,560) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹3,676 cr (up 35.4% on the same quarter last year) and net profit ₹1,127 cr (up 63.6%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹1,127 cr, up 63.6% from ₹689 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 revenue was ₹3,676 cr, up 35.4% from ₹2,715 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 EBIT was ₹1,518 cr, up 65.0% from ₹920 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 2,319 | +25.0% | 589 | +64.5% | 25.4% |
| Q4 FY25 | 2,585 | +12.2% | 662 | +23.0% | 25.6% |
| Q1 FY26 | 2,410 | +13.8% | 545 | +26.7% | 22.6% |
| Q2 FY26 | 2,715 | +16.1% | 689 | +35.1% | 25.4% |
| Q3 FY26 | 2,604 | +12.3% | 583 | −1.0% | 22.4% |
| Q4 FY26 | 2,831 | +9.5% | 751 | +13.4% | 26.5% |
| Q1 FY27 | 3,080 | +27.8% | 902 | +65.5% | 29.3% |
| Q2 FY27 | 3,676 | +35.4% | 1,127 | +63.6% | 30.7% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 38.4% in FY2026, against 44.9% in FY2022. ROE was 16.5% and ROCE 22.4% in FY2026.
EBITDA margin improved from 35.5% to 37.4% of revenue.
Rule MARGIN_EXPANDED_YOY
EBITDA margin has ranged from 32.4% to 44.6% over 4 years and sits at 37.4% now.
It had little or no debt in FY2026 (debt-to-equity 0.00x). Operating cash flow was 1.04x net profit.
Free cash flow has been positive in 5 of the last 5 years.
Rule FCF_CONSISTENTLY_POSITIVE
Within its 12-company Pharmaceuticals peer group, it ranks 5 of 12 on return on equity and 1 of 12 on EBITDA margin. Its P/E of 88.3 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
DIVISLAB · 7th of 12 · set median 14.8%
DIVISLAB · 1st of 12 · set median 28.7%
DIVISLAB · 5th of 12 · set median 14.4%
DIVISLAB · 10th of 12 · set median 45.3×
Trades at 88.25× earnings — 95% above the pharmaceuticals median of 45.29×.
Rule PE_ABOVE_PEERS
On the trailing twelve months. Last full year: P/E 115.6× · P/S 26.8× · ROE 16.2%. TTM and full-year profit and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 73.3% over 1 year, up 201% over 3 years (44.4% a year) and up 134% over 5 years (18.5% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 3.2% below its 52-week high.
Over 4 years the stock returned 44.4% a year while profit shrank 3.5% a year.
Rule STOCK_RAN_AHEAD
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 8,880 | 7,625 | 7,665 | 9,198 | 10,388 |
| Total income | 8,991 | 7,974 | 8,002 | 9,550 | 10,894 |
| EBITDA | 3,988 | 2,697 | 2,511 | 3,331 | 3,994 |
| Profit before tax | 3,677 | 2,354 | 2,132 | 2,929 | 3,436 |
| Net profit | 2,949 | 1,808 | 1,576 | 2,209 | 2,607 |
| EPS (₹) | 111.1 | 68.1 | 59.4 | 83.2 | 98.2 |
| Net worth | 11,691 | 12,705 | 13,484 | 14,895 | 16,711 |
| Total debt | 0 | 0 | 0 | 2 | 0 |
| Operating cash flow | 1,910 | 2,448 | 1,266 | 1,650 | 2,711 |
| Free cash flow | 1,196 | 1,976 | 264 | 213 | 195 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | -14.1 | 0.5 | 20.0 | 12.9 |
| Profit growth YoY | — | -38.7 | -12.8 | 40.2 | 18.0 |
| Profitability | |||||
| EBITDA margin % | 44.9 | 35.4 | 32.8 | 36.2 | 38.4 |
| Net margin % | 32.8 | 22.7 | 19.7 | 23.1 | 23.9 |
| Return on equity % | 25.2 | 14.8 | 12.0 | 15.6 | 16.5 |
| Return on capital % | 31.5 | 19.3 | 16.3 | 20.6 | 22.4 |
| Leverage & cash | |||||
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash flow ÷ profit | 0.65 | 1.35 | 0.80 | 0.75 | 1.04 |
| Current ratio | 7.10 | 8.56 | 7.60 | 7.03 | 5.47 |